Modality
siRNA
MOA
GLP-1ag
Target
AHR
Pathway
Apoptosis
PompeMelanoma
Development Pipeline
Preclinical
~Oct 2023
→ ~Jan 2025
Phase 1
Apr 2025
→ May 2031
Phase 1Current
NCT04810456
1,631 pts·Pompe
2025-04→2031-05·Recruiting
1,631 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-175.1y awayPh2 Data· Pompe
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2031-05-17 · 5.1y away
Pompe
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04810456 | Phase 1/2 | Pompe | Recruiting | 1631 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR |